Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Abstract

Background Heterozygous familial hypercholesterolaemia is characterised by low cellular uptake of LDL cholesterol, increased plasma LDL cholesterol concentrations, and premature cardiovascular disease. Despite intensive statin therapy, with or without ezetimibe, many patients are unable to achieve recommended target levels of LDL cholesterol. We investigated the effect of PCSK9 inhibition with evolocumab (AMG 145) on LDL cholesterol in patients with this disorder. Methods This multicentre, randomised, double-blind, placebo-controlled trial was undertaken at 39 sites (most of which were specialised lipid clinics, mainly attached to academic institutions) in Australia, Asia, Europe, New Zealand, North America, and South Africa between Feb 7 and Dec 19, 2013. 331 eligible patients (18-80 years of age), who met clinical criteria for heterozygous familial hypercholesterolaemia and were on stable lipid-lowering therapy for at least 4 weeks, with a fasting LDL cholesterol concentration of 2·6 mmol/L or higher, were randomly allocated in a 2:2:1:1 ratio to receive subcutaneous evolocumab 140 mg every 2 weeks, evolocumab 420 mg monthly, or subcutaneous placebo every 2 weeks or monthly for 12 weeks. Randomisation was computer generated by the study sponsor, implemented by a computerised voice interactive system, and stratified by LDL cholesterol concentration at screening (higher or lower than 4·1 mmol/L) and by baseline ezetimibe use (yes/no). Patients, study personnel, investigators,…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(14)61399-4

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Cited by

See all 756

Metadata

Authors
Raal, F. J., Stein, E. A., Dufour, R., Turner, T., Civeira, F., Burgess, L., Langslet, G., Scott, R., Olsson, A. G., Sullivan, D., Hovingh, G. K., Cariou, B., Gouni-Berthold, I., Somaratne, R., Bridges, I., Scott, R., Wasserman, S. M., & Gaudet, D.
Affiliations
  • University of the Witwatersrand (ZA)
  • Montreal Clinical Research Institute (CA)
  • Hospital Universitario Miguel Servet (ES)
  • Tygerberg Hospital (ZA)
  • Oslo University Hospital (NO)
  • Amgen (United States) (US)
  • Linköping University (SE)
  • Royal Prince Alfred Hospital (AU)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Centre Hospitalier Universitaire de Nantes (FR)
  • Amgen (United Kingdom) (GB)
  • Université de Montréal (CA)
Corresponding author
Raal, Frederick J
Venue
The Lancet
Publisher
Elsevier BV
Published
2015-01
Volume
385
Issue
9965
Pages
331-340
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2024930123
Cited by
756
References
32
Citations by year
2026: 24 · 2025: 33 · 2024: 44 · 2023: 58 · 2022: 35 · 2021: 46 · 2020: 64 · 2019: 61 · 2018: 73 · 2017: 100 · 2016: 130 · 2015: 71
FWCI
103.86
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • HAL (submittedVersion)
Funders
  • AstraZeneca
  • Meso Scale Diagnostics
  • Genzyme
  • Otsuka America
  • Merck
  • Bayer HealthCare
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Ipsen
  • AbbVie
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Abbott Laboratories
  • Amgen
  • Sanofi
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
PCSK9 inhibition, evolocumab, heterozygous familial hypercholesterolemia, LDL cholesterol lowering, ezetimibe, statin therapy, cardiovascular risk reduction, dosing frequency, lipid-lowering therapy
MeSH terms
Proprotein Convertase 9, Adolescent, Adult, Antibodies, Monoclonal, Anticholesteremic Agents, Double-Blind Method, Drug Administration Schedule, Female, Heterozygote, Humans, Hyperlipoproteinemia Type II, Injections, Subcutaneous, Cholesterol, LDL, Male, Middle Aged, Serine Endopeptidases, Treatment Outcome, Proprotein Convertases, Young Adult, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(14)61399-4
The paper
Raal, F. J., Stein, E. A., Dufour, R., Turner, T., Civeira, F., Burgess, L., Langslet, G., Scott, R., Olsson, A. G., Sullivan, D., Hovingh, G. K., Cariou, B., Gouni-Berthold, I., Somaratne, R., Bridges, I., Scott, R., Wasserman, S. M., & Gaudet, D. (2015). PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(14)61399-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.